% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • wilderguide wilderguide Jun 21, 2013 12:49 PM Flag

    Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    From the June 2013 NEJM...peer reviewed reporting on PFE's NCT00932893.
    "Conclusion: Crizotinib is superior to standard chemotherapy in patients with pre-treated advanced NSCLC with ALK rearrangement (ALK +)

    It appears likely that Crizotinib will replace chemo in advanced ALK+ NSCLC. Should this label expansion take place, ganetespib will likely catch a ride on Crizo's coattails with it 's known capacity to reverse Crizo-induced resistance. If the PFS translates to extended OS in the ongoing combo trial, G is a shoe-in...JMHO

0.343+0.072(+26.61%)Jul 22 4:00 PMEDT